Figure 2
Figure 2. ROR1 is uniformly expressed on MCL. (A) Screening for expression of ROR1 on tumor cell lines and clinical samples of MCL (Jeko-1), multiple myeloma (RPMI-8226), and follicular lymphoma (FL-18). Data of clinical samples are representative for 6 MCL, 6 multiple myeloma, and 5 follicular lymphoma patients, respectively. (B) The B-cell precursor (B-ALL) tumor cell lines BALL-1 and RCH-ACV but not SUP-B15 are positive for ROR1-protein expression by flow cytometry. (C) The tumor cells lines Jurkat (T-cell acute lymphoblastic leu-kemia), SU-DHL-4 (diffuse large B-cell lymphoma), and K562 (chronic myeloid leukemia) are negative for ROR1 surface expression. Expression of ROR1 on K562 cells after stable transfection with the ROR1-gene (K562/ROR1).

ROR1 is uniformly expressed on MCL. (A) Screening for expression of ROR1 on tumor cell lines and clinical samples of MCL (Jeko-1), multiple myeloma (RPMI-8226), and follicular lymphoma (FL-18). Data of clinical samples are representative for 6 MCL, 6 multiple myeloma, and 5 follicular lymphoma patients, respectively. (B) The B-cell precursor (B-ALL) tumor cell lines BALL-1 and RCH-ACV but not SUP-B15 are positive for ROR1-protein expression by flow cytometry. (C) The tumor cells lines Jurkat (T-cell acute lymphoblastic leu-kemia), SU-DHL-4 (diffuse large B-cell lymphoma), and K562 (chronic myeloid leukemia) are negative for ROR1 surface expression. Expression of ROR1 on K562 cells after stable transfection with the ROR1-gene (K562/ROR1).

Close Modal

or Create an Account

Close Modal
Close Modal